Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.
about
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agentGene expression analysis of a panel of cell lines that differentially restrict HIV-1 CA mutants infection in a cyclophilin a-dependent mannerCombination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease InhibitorsGenetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates.Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5αIn vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell escape mutations and covarying HLA-independent polymorphisms.Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Role of Human TRIM5α in Intrinsic Immunity.Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replicationEscape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness.Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid.Clinical significance of human immunodeficiency virus type 1 replication fitness.Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphismsReduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein.Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell typeNon-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitorsTransmission and long-term stability of compensated CD8 escape mutations.Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A.Productive replication and evolution of HIV-1 in ferret cells.Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1.Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells.HIV-1 B-subtype capsid protein: a characterization of amino acid's conservation and its significant association with integrase signatures.
P2860
Q24656023-122295A5-9D7C-46A6-BF00-823C17567991Q28541423-A0E27C73-527C-43DA-83A1-4130C1FDB10EQ33768822-1547CC3D-EBA5-49B6-9916-1682FF1DF9A9Q33808200-11A17C68-9AA1-4E79-9743-5A0D71C0ADA5Q33851789-54BCC7A8-0766-4CAE-8509-E3DA04C3DE8AQ34288181-3E99D347-BD93-43DF-AD05-AA3CA411B3BFQ34296101-331AC284-735C-4A91-8F93-774887FE32C1Q34487828-3A6F6F49-2B18-4AE1-8555-E09FC5B1B837Q34545760-E4C5605D-A044-47E1-99D4-02D78491B91FQ35237036-4CF2D74E-D4CA-4FA2-A662-C048910A67BEQ35831267-37160E22-788B-4B4C-A1AA-FA438651C498Q36315510-6FA44BF4-CA88-4C37-87B3-032F55FE2FABQ36315572-6F916B07-2F29-4E9A-B907-6DA014646B58Q36414578-7596247F-49E4-4206-8511-0F0D0CBC9275Q36506829-26F57191-EA80-48EE-B1F2-278B5F587249Q36673297-01902DA2-587F-4F3D-B993-6B81E1C85916Q36969857-E1FFA9A0-7E0F-4E35-922A-E4C2EBA328CEQ36993953-30A1EF56-3669-4FFF-A8EB-A8B371FBD53CQ37110710-96701534-A0F8-475E-BC00-D5E63F77C800Q37121420-3A809311-7470-499B-AD5A-D59CF47FFD5BQ37127869-513DCEC3-1444-4685-A8DC-5091CBC3CD46Q37145270-BFCABB0A-45A8-44C5-8EE0-900E5B442D27Q37410802-BA8A7A07-CB79-416E-8474-D7C7189DD6E4Q38997444-D5D0DC85-7D62-4755-9FC7-B5A8AD55256FQ40688534-50417808-0C59-46F2-90F6-EDFF1BC575C2Q41824328-0BFFAC5B-7D64-470E-B412-AF9094C4E1A6Q41987358-DA426A41-40C5-4A5E-A4ED-8343F1A5FBF0Q42240376-2CECFA44-A783-4E04-A047-1B65F73CD6C4
P2860
Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Altered HIV-1 Gag protein inte ...... ions in the CypA binding loop.
@en
type
label
Altered HIV-1 Gag protein inte ...... ions in the CypA binding loop.
@en
prefLabel
Altered HIV-1 Gag protein inte ...... ions in the CypA binding loop.
@en
P2093
P2860
P356
P1476
Altered HIV-1 Gag protein inte ...... ions in the CypA binding loop.
@en
P2093
Arun K Ghosh
Damaris D Yeh
Debananda Das
Hiroaki Mitsuya
Hiroyuki Gatanaga
Khaja A Hussain
Yasuhiro Suzuki
P2860
P304
P356
10.1074/JBC.M505920200
P407
P577
2005-11-07T00:00:00Z